Houston Kirsty A, Gibb Jack G, Maitland Kathryn
Department of Paediatrics, Faculty of Medicine, Imperial College, London, W2 1PG, UK.
KEMRI-Wellcome Trust Research Programme, Kilifi, 80108, Kenya.
Wellcome Open Res. 2017 Oct 27;2:66. doi: 10.12688/wellcomeopenres.12357.3. eCollection 2017.
: Diarrhoea complicates over half of admissions to hospital with severe acute malnutrition (SAM). World Health Organization (WHO) guidelines for the management of dehydration recommend the use of oral rehydration with ReSoMal (an oral rehydration solution (ORS) for SAM), which has lower sodium (45mmols/l) and higher potassium (40mmols/l) content than old WHO ORS. The composition of ReSoMal was designed specifically to address theoretical risks of sodium overload and potential under-treatment of severe hypokalaemia with rehydration using standard ORS. In African children, severe hyponatraemia at admission is a major risk factor for poor outcome in children with SAM complicated by diarrhoea. We therefore reviewed the evidence for oral rehydration therapy in children with SAM. : We conducted a systematic review of randomised controlled trials (RCTs) on 18 July 2017 comparing different oral rehydration solutions in severely malnourished children with diarrhoea and dehydration, using standard search terms. The author assessed papers for inclusion. The primary endpoint was frequency of hyponatraemia during rehydration. : Six RCTs were identified, all published in English and conducted in low resource settings in Asia. A range of ORS were evaluated in these studies, including old WHO ORS, standard hypo-osmolar WHO ORS and ReSoMal. Hyponatraemia was observed in two trials evaluating ReSoMal, three children developed severe hyponatraemia with one experiencing convulsions. Hypo-osmolar ORS was found to have benefits in time to rehydration, reduction of stool output and duration of diarrhoea. No trials reported over-hydration or fatalities. : Current WHO guidelines strongly recommend the use of ReSoMal based on low quality of evidence. Studies indicate a significant risk of hyponatraemia on ReSoMal in Asian children, none have been conducted in Africa, where SAM mortality remains high. Further research should be conducted in Africa to evaluate optimal ORS for children with SAM and to generate evidence based, practical guidelines.
在因重度急性营养不良(SAM)而住院的患者中,超过半数会出现腹泻并发症。世界卫生组织(WHO)的脱水管理指南推荐使用ReSoMal进行口服补液(一种用于SAM的口服补液盐(ORS)),其钠含量(45毫摩尔/升)低于旧版WHO ORS,钾含量(40毫摩尔/升)高于旧版WHO ORS。ReSoMal的成分经过专门设计,以应对钠过载的理论风险以及使用标准ORS补液时严重低钾血症可能治疗不足的问题。在非洲儿童中,入院时严重低钠血症是患有腹泻并发症的SAM儿童预后不良的主要危险因素。因此,我们回顾了SAM儿童口服补液治疗的证据。
我们于2017年7月18日对随机对照试验(RCT)进行了系统评价,使用标准检索词比较不同口服补液盐在患有腹泻和脱水的重度营养不良儿童中的效果。作者评估论文以确定是否纳入。主要终点是补液期间低钠血症的发生率。
共识别出6项RCT,均以英文发表,在亚洲的资源匮乏地区开展。这些研究评估了一系列ORS,包括旧版WHO ORS、标准低渗WHO ORS和ReSoMal。在两项评估ReSoMal的试验中观察到低钠血症,3名儿童出现严重低钠血症,其中1名发生惊厥。发现低渗ORS在补液时间、减少粪便排出量和腹泻持续时间方面有好处。没有试验报告补液过量或死亡情况。
基于低质量证据,现行WHO指南强烈推荐使用ReSoMal。研究表明,亚洲儿童使用ReSoMal有发生低钠血症的重大风险,在非洲尚未开展相关研究,而非洲的SAM死亡率仍然很高。应在非洲开展进一步研究,以评估适合SAM儿童的最佳ORS,并制定基于证据的实用指南。